A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: pointing towards epigenetic reprogramming

HIGHLIGHTS

• who: Lorena Incorvaia et al. from the Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND.), Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo have published the article: A u201cLymphocyte MicroRNA Signatureu201d as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming, in the Journal: (JOURNAL) of 16/Nov/2020
• what: The analysis showed that miRNAs are potential molecular mediators through which nivolumab may exert its anticancer activity. Through microarray analysis . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.